News MediWound Ltd.

Equities

MDWD

IL0011316309

Real-time Estimate Cboe BZX Other stock markets 13:45:00 2024-05-03 EDT			5-day change	1st Jan Change
18.67 ^USD	-0.90%		+2.33%	+83.53%

03-21	MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	CI
03-21	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	04-25	GL
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	04-25	AQ
MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	03-21	CI
Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024	03-21
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M	03-21	MT
MediWound: Q4 Earnings Snapshot	03-21	AQ
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	03-21	GL
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	03-14	GL
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	03-14	AQ
Sector Update: Health Care Stocks Mixed Late Afternoon	02-12	MT
MediWound Shares Rise After Positive Results From EscharEx Comparison Study	02-12	MT
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study	02-12	GL
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study	02-12	CI
MediWound to Participate in Two Upcoming Investor Conferences	02-05	GL
MediWound to Participate in Two Upcoming Investor Conferences	02-05	AQ
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA	01-09	MT
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	01-09	GL
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	01-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MediWound Ltd.

Equities

MDWD

IL0011316309

Summary

Filters